Company Overview and News

17
Value On Tap: Premium Brands At A Discount Price With Molson Coors

2018-06-19 seekingalpha
Further volume declines are priced in after a seasonally bad quarter that caused a knee-jerk reaction from investors.
TAP BUD

29
Is Molson Coors Brewing Co Stock Set to Rebound 20%?

2018-06-12 investorplace
Investors in Molson Coors Brewing Co (NYSE:TAP) have to be disappointed so far this year. TAP stock is down more than 22% so far in 2018 and more than 27% over the past 12 months. This is compared to the 4.25% year-to-date gain in the SPDR S&P 500 ETF Trust (NYSEARCA:SPY). While Molson now yields 2.6%, investors have to be asking themselves if it’s time to pass on this brew and look for a more refreshing stock.
TAP STZ.B BUD STZ SAM DEO

6
TAP / Molson Coors Brewing Co. 8-K (Current Report)

2018-06-06 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TAP

936
3
TAP / Molson Coors Brewing Co. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8U(# @;V)J#3P\+TQI;F5A
TAP

3
TAP / Molson Coors Brewing Co. null

2018-05-31 sec.gov
April 9, 2018
TAP

3
TAP / Molson Coors Brewing Co. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED7!E+T=R;W5P+U,O5')A;G-P87)E;F-Y M+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S(# ^/@T*96YD M;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#$U M,S(^/@T*
TAP

3
TAP / Molson Coors Brewing Co. 8-K (Current Report)

2018-05-27 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TAP

53
7 Consumer Goods Stocks That Will Rise Again | InvestorPlace

2018-05-11 investorplace
With the new inflation numbers coming in under expectations, that’s a bullish sign that the Federal Reserve won’t be adding more hikes to interest rates, at least for now.
TAP SJM IRBT CAG MHK 500570 TATAMOTORS TTM DF

82
5 Undervalued Large-Cap Stocks For Value Investors - May 2018

2018-05-06 seekingalpha
TAP, CMCSA, LNC, T, and CAH are all rated as suitable for the Defensive Investor and/or the Enterprising Investor following the ModernGraham approach.
TAP LNC CCV.CL CCV CMCSA LNC.WS CAH CCZ CMCSK

3
Molson Coors Brewing Shares Sink on Earnings and Revenue Misses

2018-05-02 investorplace
Molson Coors Brewing Co (NYSE:TAP) stock was hit hard on Wednesday after releasing a poor earnings report for the first quarter of the year.
TAP

94
3 Stocks Tanking Over 15% on Earnings

2018-05-02 marketrealist
It has been a highly volatile earnings season thus far, as the market is punishing stocks for the slightest misstep. With this in mind, let’s take a quick look at three stocks that are falling sharply following their earnings releases:
TAP DBD SNAP

109
Snap, Molson Coors Plunge into Wednesday’s 52-Week Low Club

2018-05-02 247wallst
May 2, 2018: Here are four stocks trading with heavy volume among 97 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 8 to 7 and on the Nasdaq, advancers led decliners by about 5 to 4.
TAP T MDLZ SNAP

5
TAP / Molson Coors Brewing Co. 10-Q (Quarterly Report)

2018-05-02 sec.gov
Document Use these links to rapidly review the document Table of Contents
TAP

4
TAP / Molson Coors Brewing Co. MOLSON COORS BREWING COMPANY 8-K (Current Report)

2018-05-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAP

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TAP / Molson Coors Brewing Co. on message board site Silicon Investor.

MRSA - Methicillin-resistant Staphylococcus aureus News for Staples Stock owners.
Metaphysics and Spiritual Practices THE CLOWN FREE STAPH INFECTION ZONE
Catapult Communications Inc (CATT) Should the tape be shown to the world?
Sex, Lies and Videotape AL GOREu0027S - TOILET TO TAP PROGRAM
TPT - TAPPIT RESOURCES LTD Staples (SPLS)
CUSIP: 60871R209